Identification of Drugs Inducing Phospholipidosis by Novel in vitro Data
暂无分享,去创建一个
Johannes Kornhuber | Philipp Tripal | Markus Muehlbacher | J. Kornhuber | P. Tripal | Florian Roas | Markus Muehlbacher | Florian Roas
[1] C. Lunte,et al. Distribution of Tacrine Across the Blood–Brain Barrier in Awake, Freely Moving Rats Using in Vivo Microdialysis Sampling , 2004, Pharmaceutical Research.
[2] D. Ortwine,et al. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[3] W. Daniel,et al. Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping , 2001, British journal of pharmacology.
[4] R. Lüllmann-Rauch,et al. Lipidosis induced by amphiphilic cationic drugs. , 1978, Biochemical pharmacology.
[5] Roger G. Ulrich,et al. An in Vitro Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar Bodies , 1991 .
[6] B. Kishore,et al. Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. , 2005, Chemistry and physics of lipids.
[7] Gus R Rosania,et al. Effect of Phospholipidosis on the Cellular Pharmacokinetics of Chloroquine , 2011, Journal of Pharmacology and Experimental Therapeutics.
[8] J. Seki,et al. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes. , 2008, Biochemical and biophysical research communications.
[9] G. Verheyen,et al. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.
[10] R. Anderson,et al. Carrier concentration model for n‐type silicon at low temperatures , 1989 .
[11] U. Leli,et al. Modifications of phospholipid metabolism induced by chlorpromazine, desmethylimipramine and propranolol in C6 glioma cells. , 1987, Biochemical pharmacology.
[12] S. Kacew. Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine. , 1987, Toxicology and applied pharmacology.
[13] Mesens Natalie,et al. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[14] J. Kornhuber,et al. Identification of Novel Functional Inhibitors of Acid Sphingomyelinase , 2011, PloS one.
[15] W. Risau. Differentiation of endothelium , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] R. Ulrich,et al. Drug-induced phospholipidosis: issues and future directions , 2006, Expert opinion on drug safety.
[17] Klaus R. Liedl,et al. Qualitative prediction of blood–brain barrier permeability on a large and refined dataset , 2011, J. Comput. Aided Mol. Des..
[18] J. B. Hutchins,et al. Amiodarone-induced lymphocyte toxicity and mitochondrial function. , 1996, Journal of cardiovascular pharmacology.
[19] Jasper Dingemanse,et al. Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells. , 2010, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[20] A. Ratcliffe,et al. Medicinal chemistry strategies to minimize phospholipidosis. , 2009, Current medicinal chemistry.
[21] D. Myszka,et al. Probing the mechanism of drug/lipid membrane interactions using Biacore. , 2004, Analytical biochemistry.
[22] G. Rosania,et al. Molecular imaging of intracellular drug-membrane aggregate formation. , 2011, Molecular pharmaceutics.
[23] Mark J. Reasor,et al. Drug-Induced Phospholipidosis: Are There Functional Consequences? , 2001, Experimental biology and medicine.
[24] M. J. Hazen,et al. Cellular responses associated with dibucaine-induced phospholipidosis. , 2011, Chemical research in toxicology.
[25] Y-K Lee,et al. Validation of an in vitro screen for phospholipidosis using a high-content biology platform , 2006, Cell Biology and Toxicology.
[26] Thomas Kolter,et al. Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. , 2009, Biochimica et biophysica acta.
[27] M. Samanta,et al. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease , 2009, Journal of Neuroscience Methods.
[28] K. Hostetler,et al. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. , 1985, Biochemistry.
[29] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[30] B Müller-Oerlinghausen,et al. The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.
[31] Matthew J Sykes,et al. Characterisation of the Binding of Cationic Amphiphilic Drugs to Phospholipid Bilayers Using Surface Plasmon Resonance , 2007, ChemMedChem.
[32] Carl Alden,et al. Biomarkers to monitor drug-induced phospholipidosis. , 2007, Toxicology and applied pharmacology.
[33] Santiago Vilar,et al. Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. , 2010, Journal of molecular graphics & modelling.
[34] J. Kornhuber,et al. Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications , 2010, Cellular Physiology and Biochemistry.
[35] M. Hollinger. Drug-Induced Lung Toxicity , 1993 .
[36] David Furcy,et al. Limited Discrepancy Beam Search , 2005, IJCAI.
[37] Nigel Greene,et al. Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential , 2007, J. Chem. Inf. Model..
[38] R. Baselt,et al. Therapeutic and toxic concentrations of more than 100 toxicologically significant drugs in blood, plasma, or serum: a tabulation. , 1975, Clinical chemistry.
[39] K. Sandhoff,et al. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. , 1994, Biological chemistry Hoppe-Seyler.
[40] K. Sandhoff,et al. Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. , 2005, Annual review of cell and developmental biology.
[41] Nuria E. Campillo,et al. Artificial Neural Networks in ADMET Modeling: Prediction of Blood–Brain Barrier Permeation , 2008 .
[42] K. Sandhoff. Membrane lipids and degenerative lysosomal storage disorders , 2009 .
[43] Ovidiu Ivanciuc,et al. Weka machine learning for predicting the phospholipidosis inducing potential. , 2008, Current topics in medicinal chemistry.
[44] U. Kodavanti,et al. Cationic amphiphilic drugs and phospholipid storage disorder. , 1990, Pharmacological reviews.
[45] K. Abromeit. Music Received , 2023, Notes.
[46] Robert C. Glen,et al. Predicting Phospholipidosis Using Machine Learning , 2010, Molecular pharmaceutics.
[47] K. Larntz. Small-Sample Comparisons of Exact Levels for Chi-Squared Goodness-of-Fit Statistics , 1978 .
[48] R. Austin,et al. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. , 1995, Journal of pharmaceutical sciences.
[49] Mark E Cartwright,et al. Phospholipidosis in Neurons Caused by Posaconazole, without Evidence for Functional Neurologic Effects , 2009, Toxicologic pathology.
[50] P. Ros,et al. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. , 1995, Chest.
[51] R. Lüllmann-Rauch,et al. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. , 1975, CRC critical reviews in toxicology.
[52] J. Falgueyret,et al. Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. , 2004, Analytical biochemistry.
[53] A. Abe,et al. The role of negatively charged lipids in lysosomal phospholipase A2 function , 2009, Journal of Lipid Research.
[54] D. Dhumeaux,et al. Amiodarone‐induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease , 1988, Hepatology.
[55] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[56] D. Morton,et al. A Strategy for Risk Management of Drug-Induced Phospholipidosis , 2009, Toxicologic pathology.
[57] S. Sutrina,et al. Effects of lysosomotropic agents on lipogenesis. , 1986, Archives of biochemistry and biophysics.
[58] M McCarthy,et al. Hepatology , 1999, Rapid Medicine.
[59] E. Downar,et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. , 1984, Gastroenterology.
[60] Utkan Demirci,et al. Rapid automated cell quantification on HIV microfluidic devices. , 2009, Lab on a chip.
[61] P. Kinnunen,et al. Screening for the Drug–Phospholipid Interaction: Correlation to Phospholipidosis , 2009, ChemMedChem.
[62] D. Monteith,et al. In vitro assays and biomarkers for drug-induced phospholipidosis , 2006, Expert opinion on drug metabolism & toxicology.
[63] Hao Zhu,et al. Estimation of the Aqueous Solubility of Organic Molecules by the Group Contribution Approach , 2001, J. Chem. Inf. Comput. Sci..
[64] Katarzyna R Przybylak,et al. In Silico Studies of the Relationship Between Chemical Structure and Drug Induced Phospholipidosis , 2011, Molecular informatics.
[65] S. Kharb. Toxicology , 1936 .
[66] L. Lehman-Mckeeman,et al. Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[67] P. Seeman,et al. Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.
[68] Akira Abe,et al. A role for lysosomal phospholipase A2 in drug induced phospholipidosis. , 2007, Drug metabolism letters.
[69] W H Halliwell,et al. Cationic Amphiphilic Drug-Induced Phospholipidosis , 1997, Toxicologic pathology.
[70] T M Dwyer,et al. Types of interaction of amphiphilic drugs with phospholipid vesicles. , 1988, The Journal of pharmacology and experimental therapeutics.
[71] Toru Yamada,et al. Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-h after single dose administration. , 2012, Toxicology.
[72] K. von Figura,et al. Biogenesis of lysosomal membranes , 1994, FEBS letters.
[73] F. Hsieh,et al. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities , 2010, Expert opinion on drug metabolism & toxicology.
[74] B. Lord. Controls on the cell cycle. , 1986, International journal of radiation biology and related studies in physics, chemistry, and medicine.
[75] Xianlin Han,et al. Lysosomal Phospholipase A2 and Phospholipidosis , 2006, Molecular and Cellular Biology.
[76] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[77] Yi Xie,et al. Antidepressant-induced lipidosis with special reference to tricyclic compounds , 2000, Progress in Neurobiology.
[78] Takashi Nonoyama,et al. Drug-induced Phospholipidosis : Pathological Aspects and Its Prediction , 2008 .
[79] Jan Kelder,et al. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
[80] H. Goldberg,et al. Increased hepatic density and phospholipidosis due to amiodarone. , 1985, AJR. American journal of roentgenology.
[81] Thomas Singer,et al. In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. , 2012, Journal of medicinal chemistry.
[82] S. Uhlig,et al. The role of sphingolipids in respiratory disease , 2011, Therapeutic advances in respiratory disease.
[83] Randy M. Perse,et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. , 1990, Human pathology.
[84] Yukihiro Kuroda,et al. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.
[85] Jianling Wang,et al. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery. , 2011, Analytical chemistry.
[86] J Kapuscinski,et al. DAPI: a DNA-specific fluorescent probe. , 1995, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[87] M. Wehling,et al. The binding of drugs to different polar lipids in vitro. , 1979, Biochemical pharmacology.
[88] F. Crivellente,et al. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development , 2003, Cell Biology and Toxicology.
[89] P. Kinnunen,et al. Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. , 2008, Journal of medicinal chemistry.
[90] C. Masimirembwa,et al. Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models , 2008, Biopharmaceutics & drug disposition.
[91] J. Corradi,et al. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. , 2010, Chemical research in toxicology.
[92] Kenji Takami,et al. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[93] Naomi L Kruhlak,et al. Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models , 2008, Toxicology mechanisms and methods.
[94] Johannes Kornhuber,et al. Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.
[95] W. Daniel. Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[96] A. Gonzales,et al. Induction of Apoptosis by Cationic Amphiphilic Drugs Amiodarone and Imipramine , 2005, Drug and chemical toxicology.
[97] K. Sandhoff,et al. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine , 2004, FEBS letters.
[98] Prabha Garg,et al. In Silico Prediction of Blood Brain Barrier Permeability: An Artificial Neural Network Model , 2006, J. Chem. Inf. Model..
[99] J. Pauluhn. Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect. , 2005, Toxicology.
[100] Byung-Hoon Lee,et al. In vitro validation of drug-induced phospholipidosis. , 2012, The Journal of toxicological sciences.
[101] J. Kornhuber,et al. Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? , 1995, Journal of neural transmission. Supplementum.
[102] Z Hruban,et al. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. , 1984, Environmental health perspectives.
[103] Tsuyoshi Harada,et al. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[104] W. Schoonen,et al. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.
[105] Michael S Roberts,et al. Ion-Trapping, Microsomal Binding, and Unbound Drug Distribution in the Hepatic Retention of Basic Drugs , 2004, Journal of Pharmacology and Experimental Therapeutics.
[106] Guoliang Zhang,et al. Evaluation of amiodarone-induced phospholipidosis by in vitro system of 3D cultured rat hepatocytes in gel entrapment , 2010 .
[107] Elazer R. Edelman,et al. Adv. Drug Delivery Rev. , 1997 .
[108] A. Horinouchi,et al. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats , 2009, Toxicology mechanisms and methods.